Amid the disruptions of the pandemic, telehealth, mobile health (mHealth), and remote patient monitoring (RPM) have become vital to both patients and providers. Entry requirements may be reduced right now, but you will have to prove your validity and value in the near future. Do you have a plan to get the data you need?
In efforts to reduce exposure risk and redirect resources to treating COVID-19, healthcare professionals are increasing adoption of innovative forms of patient care:
- Telehealth appointments are allowing doctors to provide medical care while eliminating potential exposure.
- Monitoring patient lung and heart function, breathing, blood pressure, and other factors remotely is allowing facilities to preserve hospital beds for severe COVID-19 patients.
- mHealth applications are providing asymptomatic COVID-19 patients and symptomatic COVID-19 patients not requiring hospitalization with prevention techniques, symptom management, mental health support, and monitoring by healthcare professionals.
Increased adoption due to COVID-19 represents a unique opportunity for medtech companies to collect the data now that they will need to create compelling value propositions for sustained (and increased) adoption later. When the current crisis subsides, remote options will be highly sought after – but in a highly crowded market. The companies who will succeed long-term are the ones planning now to demonstrate, prove and communicate their validity and value to the marketplace.
At TTi, we have extensive experience in supporting remote technologies – we’ve helped accelerate market access opportunities for top device manufacturers across mHealth, telehealth, AI algorithms, SaaS, and more.